Vaccine delivery platform

Griffith Enterprise's Griffith Institute for Drug Discovery has developed a biopolymer-based technology for producing vaccines and diagnostics in high yield and purity in bacterial cells.

Unique selling point/competitive advantage

This vaccine platform technology produces biopolymer beads decorated with covalently linked and densely packed antigens, which are highly effective in inducing immunogenicity. New vaccines can be developed and ready for use within 4–6 months. This platform is applicable for any existing and emerging pathogenic threats.

Investment or collaboration opportunities

Griffith Enterprise - Griffith Institute for Drug Discovery is seeking co-development programs to apply the vaccine platform technology to the development of new vaccine candidates.


Griffith Enterprise
Phone: +61 7 3735 5489

More information

Visit Griffith Enterprise for more information.

Also consider...